Sunscreen Innovation Act
Parts of this article (those related to Infobox, See also, References, External links, Categories) need to be updated.(January 2015)
|Full title||To amend the Federal Food, Drug, and Cosmetic Act to provide an alternative process for review of safety and effectiveness of nonprescription sunscreen active ingredients and for other purposes.|
|Introduced in||113th United States Congress|
|Introduced on||March 13, 2014|
|Sponsored by||Rep. Ed Whitfield (R, KY-1)|
|Number of co-sponsors||1|
|Effects and codifications|
|Act(s) affected||Federal Food, Drug, and Cosmetic Act|
|U.S.C. section(s) affected||18 U.S.C. § 1905, 5 U.S.C. § 552, 21 U.S.C. § 351 et seq.|
|Agencies affected||United States Congress, Department of Health and Human Services, Food and Drug Administration|
The Sunscreen Innovation Act (S. 2141, Pub.L. 113–195) is a 2014 law that amended the Federal Food, Drug, and Cosmetic Act to establish an expedited process for the review and approval of over-the-counter (OTC) sunscreens. The US Food and Drug Administration (FDA) had not approved a new active ingredient in sunscreen since 1999, despite some sunscreens having been approved and used overseas for a decade. The new law gave the FDA one year to respond to the existing backlog of sunscreen ingredient approval requests, and then 18 months to reply to any future applications.
Sunscreen (also commonly known as sun screen, sunblock, suntan lotion, sunburn cream, sun cream or block out) is a lotion, spray, gel or other topical product that absorbs or reflects some of the sun's ultraviolet (UV) radiation on the skin exposed to sunlight and thus helps protect against sunburn. Depending on the mode of action, sunscreens can be classified into physical sunscreens (i.e., those that reflect the sunlight) or chemical sunscreens (i.e., those that absorb the UV light).
Medical organizations such as the American Cancer Society recommend the use of sunscreen because it aids in the prevention of squamous cell carcinomas. Many sunscreens do not block UVA radiation, which does not cause sunburn but can increase the rate of melanoma and photodermatitis, so people using sunscreens may be exposed to high UVA levels without realizing it. The use of broad-spectrum (UVA/UVB) sunscreens can address this concern. Diligent use of sunscreen can also slow or temporarily prevent the development of wrinkles and sagging skin.
Provisions of the bill
The bill would require the United States Secretary of Health and Human Services (HHS) to review and determine whether OTC sunscreens are generally recognized as safe and effective and ensure that any sunscreens marketed in the United States are appropriately labeled.
The bill would make sunscreens that have been marketed for five continuous years in the United States or other countries and in sufficient quantity eligible for review under this Act.
The bill would establish a framework for the review and approval by the Food and Drug Administration (FDA) of OTC sunscreens with new active ingredients. Sets forth time frame requirements for review. Requires applications for review to include safety and efficacy data as well as adverse drug experience information.
The bill would direct the Secretary to report on the progress made in issuing timely decisions on the safety and effectiveness of OTC sunscreens.
The bill would require the Secretary to make determinations on the testing and labeling of aerosol sunscreens and on whether a sunscreen may contain a label indicating a sun protection factor (SPF) greater than 50.
Congressional Budget Office report
This summary is based largely on the summary provided by the Congressional Budget Office, as ordered reported by the House Committee on Energy and Commerce on July 15, 2014. This is a public domain source.
H.R. 4250 would modify the review process that allows the marketing of certain new ingredients in non-prescription sunscreen based on a determination by the Food and Drug Administration (FDA) that they are generally recognized as safe and effective. The Congressional Budget Office (CBO) estimates that implementing H.R. 4250 would cost $28 million over the 2015–2019 period, assuming appropriation of the necessary amounts. H.R. 4250 would not affect direct spending or revenues; therefore, pay-as-you-go procedures do not apply.
The bill would impose private-sector mandates, as defined in UMRA, because it would allow FDA to require that marketing applications for certain sunscreen products be submitted in a new standardized format. CBO estimates that the direct cost of complying with those requirements would not exceed the annual threshold established by UMRA for private-sector mandates ($152 million in 2014, adjusted annually for inflation).
Debate and discussion
The Melanoma Research Alliance supported the bill. In a video produced by the group, a melanoma survivor said that "when I heard that there were actually ingredients that the FDA is basically holding hostage, it infuriates me, it's crazy."
In 2009, chemical company and sunscreen manufacturer Ashland Inc. "significantly expanded its existing sunscreen production facilities in Columbus, Ohio, after the FDA announced it expected to make decisions on the pending ingredient applications before the end of the year." Five years later, the FDA had still not made a decision and Ashland was unable to sell this type of sunscreen in the United States.
- "H.R. 4250 - Summary". United States Congress. Retrieved 30 July 2014.
- Hackman, Michelle (28 July 2014). "House Passes Bill to Speed FDA's Sunscreen Approvals". The Wall Street Journal. Retrieved 30 July 2014.
- Sifferlin, Alexandra (16 July 2014). "We're One Step Closer to Better Sunscreen". Time Magazine. Retrieved 30 July 2014.
- "H.R.4250 – All Actions". United States Congress. Retrieved 30 July 2014.
- "S.2141 – All Actions". United States Congress. Retrieved 5 January 2015.
- "Preventing melanoma". Cancer Research UK. Archived from the original on 22 May 2008. Retrieved 22 September 2009.
- Sunscreens | The Ageing Skin
- What You Need To Know About Skin Cancer
- Terence SC Poon, Ross StC Barnetson and Gary M Halliday (2003). "Prevention of Immunosuppression by Sunscreens in Humans Is Unrelated to Protection from Erythema and Dependent on Protection from Ultraviolet A in the Face of Constant Ultraviolet B Protection". J Invest Dermatol. 121: 184–90. doi:10.1046/j.1523-1747.2003.12317.x.
- M.C.B. Hughes; G.M. Williams; P. Baker; A.C. Green (June 4, 2013). "Sunscreen and Prevention of Skin Aging". 158 (11). Annals of Internal Medicine: 781–790.
- "CBO - H.R. 4250". Congressional Budget Office. Retrieved 30 July 2014.
- "The Sunscreen Innovation Act". Melanoma Research Alliance. Retrieved 30 July 2014.
|Wikisource has original text related to this article:|
- Library of Congress - Thomas H.R. 4250
- beta.congress.gov H.R. 4250
- GovTrack.us H.R. 4250
- OpenCongress.org H.R. 4250
- WashingtonWatch.com H.R. 4250
- Congressional Budget Office's report on H.R. 4250